Alzheimer Disease
Conditions
Brief summary
This study aims to investigate bumetanide in patients with biologically confirmed Alzheimer's disease (AD). Bumetanide is a potent diuretic administered orally and is FDA approved for the treatment of edema and hypertension. Repurposing bumetanide as a medication for AD has been proposed based on data that demonstrated its ability to flip the APOE genotype-dependent transcriptomic signatures in AD mouse and cell culture models. Critically, this discovery was subsequently explored in Electronic Health Record cohorts, which revealed that among individuals over the age of 65, bumetanide exposure was significantly associated with a lower prevalence of AD in three independent datasets. Primary Objective: To evaluate the safety and tolerability of bumetanide when administered to participants with biomarker-confirmed Alzheimer's disease. Secondary Objective: To evaluate the clinical and biomarker effects of bumetanide in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease.
Interventions
DRUGBumetanide
Bumetanide is an FDA approved loop diuretic that has been used for more than three decades to treat edema, congestive heart failure, and hypertension across the life span. It has a well-known side effect profile. Most importantly it can cause dehydration and electrolyte imbalance especially at higher doses. This medication is given to individuals at the similar age group as Alzheimer's disease patients and Alzheimer's disease or cognitive impairment do not preclude its use in patients who need it for its FDA indications. At low doses and when titrated carefully, the medication is well tolerated. However, it has not been studied specifically in Alzheimer's disease patients.
DRUGPlacebo
A placebo has no active properties and is taken orally.
Sponsors
Stanford University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
1. Bumetanide low dose, 15 participants 2. Bumetanide high dose, 15 participants 3. Placebo, 10 participants
Eligibility
Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Mild cognitive impairment or mild dementia due to Alzheimer's disease. * Alzheimer's disease medications are planned to remain stable throughout. * Willingness and ability to complete all aspects of the study including assessments, neuropsychological testing, and MRI.
Exclusion criteria
* Clinically significant abnormalities in screening laboratory tests * Chronic liver disease * Renal insufficiency * Poorly managed hypertension * Participants taking the following concomitant medications, based on the current Prescribing Information for bumetanide: lithium, drugs with ototoxic potential, drugs with nephrotoxic potential, probenecid, and indomethacin.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Related Adverse Events | 6 months | Number of participants with adverse events including clinical signs and symptoms, change in vital signs, ECGs, laboratory safety tests, and suicidality assessments. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in The Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog13) | 6 months | The ADAS-Cog evaluates cognition and is scored from 0 to 90 points with a score of 0 indicating no impairment, and a score of 90 indicating maximum impairment |
| Changed from baseline in the clinical dementia rating scale sum of boxes (CDR-SoB) | 6 months | CDR-SoB evaluates function with total possible score of 0 to 18 with higher scores indicating more impairment |
Countries
United States
Contacts
Primary ContactMina L Kim
Outcome results
None listed